About PacBio
PacBio is a company based in Menlo Park (United States) founded in 2004. PacBio has raised $395 million across 11 funding rounds from investors including Morgan Stanley, Kleiner Perkins and SoftBank Group. The company has 575 employees as of December 31, 2024. PacBio has completed 2 acquisitions, including Circulomics and Omniome. PacBio operates in a competitive market with competitors including Nanopore, Omniome, Complete Genomics, QuantuMDx and Bionano, among others.
- Headquarter Menlo Park, United States
- Employees 575 as on 31 Dec, 2024
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Pacific Biosciences Of California, Inc.
-
Annual Revenue
$154.01 M (USD)-23.19as on Dec 31, 2024
-
Net Profit
-$309.85 M (USD)-1.02as on Dec 31, 2024
-
EBITDA
-$212.1 M (USD)23.61as on Dec 31, 2024
-
Total Equity Funding
$395 M (USD)
in 11 rounds
-
Latest Funding Round
$900 M (USD), Post-IPO
Feb 10, 2021
-
Investors
Morgan Stanley
& 20 more
-
Employee Count
575
as on Dec 31, 2024
-
Investments & Acquisitions
Circulomics
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of PacBio
PacBio is a publicly listed company on the NASDAQ with ticker symbol PACB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of PacBio
Unlock access to complete
Unlock access to complete
Funding Insights of PacBio
PacBio has successfully raised a total of $395M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $900 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in PacBio
PacBio has secured backing from 21 investors, including institutional and venture fund investors. Prominent investors backing the company include Morgan Stanley, Kleiner Perkins and SoftBank Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are managed in technology and healthcare sectors by this firm.
|
Locked | Locked | Locked | |
|
Mid-stage venture capital investments and support for tech entrepreneurs.
|
Locked | Locked | Locked | |
|
Early stage venture capital firm investing in the US
|
Locked | Locked | Locked |
Investor details for PacBio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PacBio
PacBio has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Circulomics and Omniome.
Investment portfolio details for PacBio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Genome sequencing platform is provided for clinical diagnostics.
|
Locked | Locked | 2013 | Locked | |
|
Platforms for genome profiling and biomarker analysis are developed.
|
Locked | Locked | 2009 | Locked |
Complete acquisition details for PacBio
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - PacBio
Detailed financials for PacBio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pacbio Comparisons
Peer comparison for PacBio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PacBio
PacBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nanopore, Omniome, Complete Genomics, QuantuMDx and Bionano, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Nanopore-based electronic systems for single-molecule analysis are developed.
|
|
| Locked | Locked | Locked |
Genome sequencing platform is provided for clinical diagnostics.
|
|
| Locked | Locked | Locked |
DNA sequencing platform for human genome analysis is developed.
|
|
| Locked | Locked | Locked |
Handheld diagnostic and sequencing devices are developed for personalized healthcare.
|
|
| Locked | Locked | Locked |
Provider of genome analysis solutions to researchers and clinicians
|
Detailed competitors of PacBio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pacbio
Complete news archive for PacBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PacBio
PacBio was founded in 2004 and raised its 1st funding round 3 years after it was founded.
PacBio is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Christian Henry is the current CEO of PacBio.
PacBio is a funded company, having raised a total of $395M across 11 funding rounds to date.
As of Dec 31, 2024, the latest employee count at PacBio is 575.
Annual revenue of PacBio is $154.01M as on Dec 31, 2024.
PacBio was founded in 2004 in Menlo Park, United States, within the biotechnology sector. Instrument systems and associated software for real-time sequencing of single molecules are developed by the company. A sequencing platform based on two proprietary technologies is utilized to enable this process. Analytical software for refining sequence data processing and generating reports is also provided, supporting operations in genomic research across the United States.
PacBio's top competitors include Nanopore, QuantuMDx and Complete Genomics.
Yes, PacBio is publicly traded on NASDAQ under the ticker symbol PACB.
PacBio has made 2 acquisitions, including Circulomics, and Omniome.
PacBio has 21 investors. Key investors include Morgan Stanley, Kleiner Perkins, SoftBank Group, Blackstone, and AllianceBernstein.
The ticker symbol of PacBio is PACB on NASDAQ.